Appears since you posted this link he has edited that comment out of his blog.
Had he been fair, he would have quoted in context from the Reuters article, where Pearson, in an interview about Valeant and their business strategy, described his own company, along with Medicis and a couple others, as being among the "lightweights" in the pharma industry, as opposed to Big Pharma companies that they chose to not fight against. It was not a dig at Medicis, just laying out "big" players vs "smaller" ones. Pearson never mentioned their name. Author of the Reuters piece merely listed who Valeant's primary rivals are.
While there is significant competition in the dermatology arena, Valeant will be facing smaller rivals, rather than the pharmaceutical giants, which have been beating a hasty retreat from the sector as they look to narrow their focus.http://www.reuters.com/article/2011...15?feedType=RSS&feedName=hotStocksNews&rpc=43
"It's like we're in the lightweight division and we're fighting other lightweights. We're not fighting heavyweights," Pearson said. "It fits us from a scale standpoint."
Pearson's philosophy has been to stay clear of the so-called Big Pharma companies, but engage in partnerships with them instead.
Valeant's main rivals in the industry are Medicis Pharmaceuticals (MRX.N), Allergan Inc (AGN.N), as well as Stiefel Laboratories Inc, which is a unit of GlaxoSmithKline (GSK.L).
Oh, interesting it's been changed. Thank you for letting me know and for the excellent research on the other article.